Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.

Research and Markets: Brintellix (vortioxetine) Major Depressive Disorder Drug Report - Forecast and Market Analysis to 2023


Research and Markets ( has announced the addition of the "Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.

Brintellix (vortioxetine) is a multimodal antidepressant that is indicated for the treatment of MDD and was co-developed by Lundbeck and Takeda. It gained FDA approval in October 2013 and EMA approval in December 2013. Brintellix launched in the US market in January 2014 and its launch in European markets is expected during the second half of 2014 (Lundbeck, press release, December 27, 2013).


  • Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Brintellix including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Brintellix for the top eight countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Brintellix (Vortioxetine)

7 Appendix

For more information visit


Rate this press release
3 stars


Add to favourites icon Add to favourites